As Zyn­lon­ta sales dis­ap­point, ADC Ther­a­peu­tics cuts staff and pre­clin­i­cal pro­grams

ADC Ther­a­peu­tics an­nounced Tues­day morn­ing that it was lay­ing off more than 50 staffers and stop­ping work on two pre­clin­i­cal can­cer pro­grams.

ADC plans to lay off 17% of its work­force — or ap­prox­i­mate­ly 54 of its 317 em­ploy­ees, as of the end of 2022. The biotech not­ed it’s in­clud­ing con­trac­tors in its lay­off count.

The Swiss biotech is al­so stop­ping in­vest­ment in AD­CT-212, a pre­clin­i­cal an­ti­body-drug con­ju­gate for prostate can­cer, and AD­CT-701, which it had hoped to test in neu­roen­docrine tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER